Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kamyar Kalantar

Nephrology Orange, CA Medical Doctor

NPI 1457314684 CMS profile 111745

101 The City Dr S, Orange, CA 92868

Open in the dashboard

General payments

$420,989

310 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kamyar Kalantar of Orange, CA is reported in the CMS Open Payments database as having received $420,989 across 310 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $32,972 16
2024 General $3,028 2
2023 General $45,627 24
2022 General $147,432 102
2021 General $73,862 45
2020 General $34,391 29
2019 General $83,678 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kamyar Kalantar
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Kamyar Kalantar were reported at $32,972. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Kamyar Kalantar Nephrology median Middle half National median
2019 $83,678 $236 $90–$588 $163
2020 $34,391 $135 $46–$364 $114
2021 $73,862 $202 $67–$551 $132
2022 $147,432 $242 $77–$695 $149
2023 $45,627 $254 $84–$766 $160
2024 $3,028 $300 $99–$852 $164
2025 $32,972 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Fresenius Kabi USA, LLC $51,554 16 payments
  2. Fresenius USA Marketing, Inc. $50,486 65 payments
  3. Relypsa, Inc. $47,220 34 payments
  4. Daiichi Sankyo Inc. $35,795 26 payments
  5. GlaxoSmithKline, LLC. $23,014 6 payments
  6. AstraZeneca Pharmaceuticals LP $20,315 24 payments
  7. Vifor Fresenius Medical Care Renal Pharma Ltd. $18,434 9 payments
  8. Akebia Therapeutics Inc $18,091 12 payments
  9. NxStage Medical, Inc. $16,686 22 payments
  10. Calliditas Therapeutics US Inc. $16,552 9 payments
  11. Other $122,843 87 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $213,622 78 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $108,381 41 payments
  3. Travel and Lodging $46,980 78 payments
  4. Honoraria $44,566 25 payments
  5. Food and Beverage $6,962 86 payments
  6. Gift $475 1 payment
  7. Education $3 1 payment
Products named General payments · program years 2019–2025
  1. Velphoro Phosphate binder for ESRD $44,871 54 payments
  2. INJECTAFER Anemia $42,906 23 payments
  3. NXSTAGE SYSTEM ONE $16,686 22 payments
  4. TARPEYO $13,829 7 payments
  5. LOKELMA $12,055 21 payments
  6. Auryxia $10,761 9 payments
  7. KRYSTEXXA $10,500 10 payments
  8. Velphoro Potassium Binder $9,701 5 payments
  9. Veltassa $6,982 4 payments
  10. INJECTAFER Iron Deficiency Anemia $6,766 5 payments
  11. Other $27,030 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

310 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record